Stock & Company Details
Vertex Pharmaceuticals, Inc. $VRTX
Price:
N/A
N/A
254M
$128B
52 Week High:
N/A
10 Day Average Volume:
N/A
29.28
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
VRTX technical indicators
Latest Vertex Pharmaceuticals, Inc. (VRTX) indicator readings as of 2026-10-09.
VRTX's 14-day RSI is 45.6, in neutral territory. At $510.08 it is trading 7.4% above its 200-day moving average of $474.90, and below its 50-day average of $520.46. Price sits in the middle of its Bollinger Bands ($497.58 to $530.04). ADX reads 19.1, indicating a range-bound market rather than a trend.
VRTX backtested strategy results
How 4 rule-based strategies performed on Vertex Pharmaceuticals, Inc. (VRTX) over recent history, last backtested 2026-09-09. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +22.5% | 60% | 5 | -25.2% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -51.5% | 27% | 33 | -59.1% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -38.5% | 20% | 40 | -46.3% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +52.0% | 93% | 15 | -14.9% |
Overview
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Finance Bot
Ask your questions
Start by typing a question below.
